Premium
The prognostic value of long noncoding RNA MEG3 expression in the survival of patients with cancer: A meta‐analysis
Author(s) -
Binabaj Maryam Moradi,
Bahrami Afsane,
Bahreyni Amirhossein,
Shafiee Mojtaba,
Rahmani Farzad,
Khazaei Majid,
Soleimanpour Saman,
Ghorbani Elnaz,
Fiuji Hamid,
Ferns Gordon A.,
Ryzhikov Mikhail,
Avan Amir,
Hassanian Seyed Mahdi
Publication year - 2018
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.27276
Subject(s) - meg3 , carcinogenesis , long non coding rna , hazard ratio , cancer , meta analysis , breast cancer , oncology , medicine , cancer research , survival analysis , biology , gene , rna , genetics , confidence interval
Long noncoding RNAs (lncRNAs) play an important role in carcinogenesis and cancer progression. lncRNA maternally expressed gene 3 (MEG3) is a tumor suppressor that is downregulated in several cancers. However, its prognostic value in human malignancies remains controversial. We have therefore undertaken a meta‐analysis to explore the relationship between cancer survival and the expression of lncRNA MEG3. A systematic literature search identified 13 potentially eligible investigations comprising 1733 patients in nine different cancer types. In the pooled analysis, a low expression of MEG3 was associated with low overall survival (OS) in patients with cancer having a combined hazard ratio (HR) of 0.830 (HR = 0.83; 95% CI: 0.70‐0.98; p = 0.03; random effect model). However, subgroup analysis according to cancer type revealed that MEG3 expression was not associated with better OS in gastrointestinal cancer (HR = 0.58, 95% CI = 0.33‐1.03; p = 0.06), and patients with breast cancer (HR = 0.85, 95% CI: 0.12‐5.88; p = 0.87). In conclusion, our results demonstrate that only in the pooled analysis, there was a significant relationship between MEG3 expression and cancer survival. Further investigation of other molecular biomarkers involved in tumorigenesis‐related pathways is necessary.